Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Diagnosis

Significance of incidental parotid gland 18F-FDG uptake on PET/CT and its impact on patient management

Anthony Ciarallo, William Makis, Akshat Gotra and Marc Hickeson
Journal of Nuclear Medicine May 2012, 53 (supplement 1) 448;
Anthony Ciarallo
1Nuclear Medicine, McGill University, Montreal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Makis
2Nuclear Medicine, Brandon Regional Health Center, Brandon, MB, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akshat Gotra
1Nuclear Medicine, McGill University, Montreal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Hickeson
1Nuclear Medicine, McGill University, Montreal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

448

Objectives To evaluate the incidence and clinical significance of unexpected focal uptake of 18F-FDG in the parotid glands on PET/CT in patients with known or suspected non-head and neck primary malignancy.

Methods A retrospective review was conducted on 7252 consecutive patients who underwent FDG PET/CT scans for various oncologic indications over the course of 48 months. Patients with known or suspected head and neck cancer (HN) were excluded from the study. FDG uptake in the parotid glands was quantified with maximum standardized uptake value (SUVmax) corrected for body weight. Outcome was assessed by histological correlation when available, or by clinical and imaging follow up.

Results Incidental parotid FDG uptake was identified in 27 of 7252 patients (0.4%). Twenty-five had available histology and/or follow-up. One of 25 patients (4.0%) had histologically confirmed malignancy, with SUVmax of 7.4. The patient was known for follicular lymphoma and was found to have lymphomatous involvement of the left parotid gland following the PET/CT scan. In the remaining 24 patients considered to have benign uptake by histological (n=9) and/or clinical (n=15) correlation, mean SUVmax was 6.5 (SD +/- 3.6, range: 1.9 - 18.3).

Conclusions As the largest Western study of FDG-avid parotid incidentalomas, we found 0.4% of oncologic patients had unexpected focal parotid uptake in whom 4% had proven malignancy. Previously reported malignancy rates in FDG-avid parotid incidentalomas vary widely from 0-29%. In this study, one of 4 lymphoma patients had unexpected disease involvement of the parotid gland. Interestingly, two previous studies both detected lymphoma in 1 of 2 malignant cases in their respective populations. Consequently, special attention should be given to parotid gland FDG uptake in patients with known or suspected lymphoma as they appear to have a higher predilection for parotid gland malignancy than other oncologic patients

Back to top

In this issue

Journal of Nuclear Medicine
Vol. 53, Issue supplement 1
May 2012
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Significance of incidental parotid gland 18F-FDG uptake on PET/CT and its impact on patient management
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Significance of incidental parotid gland 18F-FDG uptake on PET/CT and its impact on patient management
Anthony Ciarallo, William Makis, Akshat Gotra, Marc Hickeson
Journal of Nuclear Medicine May 2012, 53 (supplement 1) 448;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Significance of incidental parotid gland 18F-FDG uptake on PET/CT and its impact on patient management
Anthony Ciarallo, William Makis, Akshat Gotra, Marc Hickeson
Journal of Nuclear Medicine May 2012, 53 (supplement 1) 448;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Clinical Diagnosis

  • The Significance of Adrenal Hypermetabolism on FDG PET/CT Scans of Various Cancer Patients: Any Clues for Differential Diagnosis?
  • Bone scan response to newer therapies in castration resistant prostate cancer.
  • Preliminary analysis of dynamic [68Ga]PSMAHBED-CC PET/MRI in primary prostate cancer
Show more Oncology: Clinical Diagnosis

Head & Neck II

  • The value of post-therapy F-18 FDG PET/CT surveillance scans in the detection of recurrent nasopharyngeal carcinoma
  • Prognostic value of pretreatment 18F-FDG PET/CT parameters including visual evaluation in patients with head and neck squamous cell carcinoma
  • Does PET/CT improve patient management after curative-intent radiotherapy (RT) for head & neck squamous cell carcinoma (HNSCC)?
Show more Head & Neck II

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire